Brief: Arch Biopartners Receives Health Canada Authorization To Amend Phase Ii Trial Protocol For Lsalt Peptide
16/03/2021 12:57
March 16 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES HEALTH CANADA AUTHORIZATION TO
AMEND
PHASE II TRIAL PROTOCOL FOR LSALT PEPTIDE
Source text for Eikon: ID:nGNX5nldkk
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide